Anavex Life Sciences Corp (AVXL)

[sokol]

The AAIC 2022 poster says this: Study of the Mechanism of Action of Blarcamesine (ANAVEX®2-73): Whole Blood Transcriptomics Analysis (RNAseq)
Identifies Treatment Impact on Compensatory Pathways by Restoring Key Neurodegenerative Pathways Functionality,
including Alzheimer’s and Parkinson’s Disease Pathways

https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_c5813c517d9f4ca5aacbeb719508827a.pdf

In other words, Blarcamesine restored dysregulated genes associated with Alzheimer's and Parkinson's.  If so, was that restoration evident in all patients treated with Blarcamesine versus no restoration in the placebo patients?  More importantly, did all treated patients show some degree of improvement or decline in the progression of the diseases?  Or was it that the restoration occurred only in those patients treated with the Blarcamesine high dose?  

What I am driving at is this:  If the gene restoration occurred in all or most all patients treated with Blarcamesine compared to no such repair in placebo patients, this would be important.  It would involve a more significant number of patients showing some positive response to the drug.  If so, this would go a long way to demonstrate that the drug has a positive biological response in the body of a significant number of Blarcamesine-treated patients.